Julie R. Brahmer

5 ta ish

Centro de Investigación Biomédica en Red de Cáncer

1. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

   Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer +27

   MaqolaOAOchiq kirish20123 iqtibos

   ABIABI:AkademIndex/2026.other.132162

2. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

   Julie R. Brahmer, Karen L. Reckamp, Paul Baas +22

   MaqolaOAOchiq kirish20153 iqtibos

   ABIABI:AkademIndex/2026.other.170111

3. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

   Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson +15

   MaqolaOAOchiq kirish20162 iqtibos

   ABIABI:AkademIndex/2026.other.170118

4. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

   Julie R. Brahmer, Christina Lacchetti, Bryan J. Schneider +26

   Maqola20182 iqtibos

   ABIABI:AkademIndex/2026.other.769170

5. Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

   Matthew D. Hellmann, Luis Paz‐Ares, Reyes Bernabe Caro +23

   Maqola20192 iqtibos

   ABIABI:AkademIndex/2026.other.826278